Core Viewpoint - Changjiang Life Science Technology (00775) experienced a nearly 7% increase in stock price, attributed to the presentation of significant advancements in cancer immunotherapy at the SITC 2025 conference [1] Group 1: Company Developments - The company showcased research results on tumor growth inhibition, focusing on innovative cancer vaccines targeting TROP2, PRAME, and PD-L1 [1] - Two innovative vaccines targeting the TROP2 protein were disclosed, which is highly expressed in various cancers including breast, lung, and colorectal cancers [1] - The company also announced the development of a vaccine that simultaneously targets PD-L1 and PRAME, with notable T-cell activation effects [1] Group 2: Research Outcomes - In a preventive lung cancer model, the vaccine demonstrated a tumor growth inhibition rate exceeding 95% after administration [1] - The vaccine maintained its defensive capability against tumor re-challenge tests three months post-administration, indicating the potential for long-lasting immune memory [1]
港股异动 | 长江生命科技(00775)午后涨近7% 公司在2025 SITC年会展示抑制肿瘤生长研发成果